These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11499268)

  • 1. [ACE inhibitors for therapy of cardiac and kidney insufficiency].
    Schwaab B; Böhm M
    Dtsch Med Wochenschr; 2001 Jul; 126(28-29):831-2. PubMed ID: 11499268
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
    Ahmed A; Centor RM; Weaver MT; Perry GJ
    Am Heart J; 2005 Apr; 149(4):737-43. PubMed ID: 15990761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angiotensin-II-antagonism: new hope for the management of cardiac insufficiency].
    Z Kardiol; 1997 Sep; 86(9 Suppl Angio):1-4. PubMed ID: 9373391
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ACE inhibitors and kidney failure in heart failure].
    G Ital Cardiol; 1994 May; 24(5):645-8. PubMed ID: 8076748
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
    Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
    Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM; Kamper AL
    Ugeskr Laeger; 2003 Oct; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract]   [Full Text] [Related]  

  • 10. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
    MMW Fortschr Med; 2002 Oct; 144(40):49. PubMed ID: 12440300
    [No Abstract]   [Full Text] [Related]  

  • 12. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M
    Heart Fail Monit; 2002; 2(3):85-7. PubMed ID: 12634889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
    Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].
    Ditiatkov AE; Tikhonov VA; Radzevich AE
    Probl Tuberk; 2001; (8):37-9. PubMed ID: 11767390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined cardio-renal failure: a key factor in heart failure progression and therapy].
    Caramelo C; Gil P
    Rev Esp Cardiol; 2006 Feb; 59(2):87-90. PubMed ID: 16540027
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK; Barker S
    Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.